AstraZeneca enters the BACE inhibitor Phase III stakes
This article was originally published in Scrip
Executive Summary
On the back of its recent deal with Lilly, AstraZeneca has moved its BACE inhibitor AZD3293 into Phase III testing in mild Alzheimer's disease and mild cognitive impairment, making it the second late-stage drug still in contention in this novel, but very high-risk drug class. The pipeline advance also puts the firm well on track to deliver on its Phase III pipeline promises for this year.